HEARTSCIENCES INC (HSCS) Stock News
NASDAQ:HSCS - Nasdaq - US42254E3027 - Common Stock - Currency: USD
HSCS Latest News, Press Relases and Analysis
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company’s strong revenue growth reported in its Q1 2025 results. Woo indicated that the commercialization of RenovoCath and anticipated positive clinical data in Q3 will […]
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with...
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease...
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence...
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) (
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) (
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) (
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...